News
ALRN
3.780
-4.30%
-0.170
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics, Inc. Is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines. Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences. Aileron is developing drugs to address unmet medical needs in orphan pulmonary and fibrosis indications.
Barchart · 1d ago
Weekly Report: what happened at ALRN last week (0429-0503)?
Weekly Report · 1d ago
AILERON THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN REGISTERED DIRECT OFFERING OF UP TO APPROXIMATELY $40 MILLION
Reuters · 4d ago
Press Release: Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 million. Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of about $30 million from exercise of three-year warrants. Aileron is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications.
Dow Jones · 4d ago
AILERON THERAPEUTICS INC: ENTERED INTO AN UNDERWRITING AGREEMENT WITH TITAN PARTNERS GROUP LLC, AS UNDERWRITER
Reuters · 6d ago
Aileron Announces Positive Data From Phase 1b Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
NASDAQ · 6d ago
Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M
Healthcare Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M. ALRN -3.29% premarket to $4.4. The offering is expected to close on or about May 3.
Seeking Alpha · 6d ago
Aileron Therapeutics announces positive data from its early stage pulmonary fibrosis treatment trial
Seeking Alpha · 6d ago
Press Release: Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced at-The-Market Under Nasdaq Rules of up to Approximately $40 million. Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately Aileron is a biopharmaceutical company advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis.
Dow Jones · 6d ago
Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
Low-dose LTI-03 (2.5 mg BID) reduced expression of profibrotic proteins and increased expression of a biomarker indicative of epithelial health. Positive trend was observed in seven of eight IPF biomarkers evaluated. Company to host conference call on May 1st.
Benzinga · 6d ago
AILERON THERAPEUTICS INC: RESULTS SHOW LTI-03 TO BE GENERALLY WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS (SAES) REPORTED
Reuters · 6d ago
AILERON THERAPEUTICS INC: POSITIVE TREND WAS OBSERVED IN SEVEN OF EIGHT IPF BIOMARKERS EVALUATED
Reuters · 6d ago
Aileron Therapeutics Inc: [Amend]Annual Report
Press release · 04/29 13:27
Weekly Report: what happened at ALRN last week (0422-0426)?
Weekly Report · 04/29 12:29
Weekly Report: what happened at ALRN last week (0415-0419)?
Weekly Report · 04/22 12:12
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
CGC, GENE and HOLO among mid-day movers
Seeking Alpha · 04/18 16:42
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 04/18 16:32
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. Aileron Therapeutics (NASdaq:ALRN) and 23andMe Holding moved upwards. Losers SeaStar Medical Holding and Aptorum Gr stock decreased by 27.0% during the session.
Benzinga · 04/18 16:31
Aileron Therapeutics Filed U.S. Patent Application #20240124518: Methods For Preparing Purified Polypeptide Compositions
Benzinga · 04/18 15:50
More
Webull provides a variety of real-time ALRN stock news. You can receive the latest news about Aileron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALRN
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.